MDS

In patients with high-risk myelodysplastic syndromes, hypomethylating agents are underutilized, particularly among older, female and non-White patients.

I never would have survived through 15 years of cancer without my two passions: faith and writing.

Butterflies are believed to be a symbol of resurrection and hope. This is an inspiring story about this phenomenon.

I’ve survived rare blood cancer for 15 years, but the lasting side effects have taken a toll — even so, I still find purpose, joy and reasons to keep going.

I describe what it is like to have an “invisible” cancer.

As a cancer survivor I explain the importance of looking forward to life.

After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.

In an upside-down, topsy-turvy world, cancer can be a distraction for us.

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.

As a cancer survivor, I talk about where to look for the light when in utter darkness.

As a cancer survivor, I describe battling both cancer and infections and the toll it takes on my body.

I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to others.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

As a survivor of MDS, I’ve learned to make the best of every day and to be thankful for life. Sometimes this means avoiding others who are less grateful.

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.

Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS.

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be discontinued.

I spent my life racing against time, until my cancer diagnosis forced me to hit the brakes.